Overall, in public datasets, we observed 1-2% of MDS/AML patients had P/LP CHEK2 variants with a comparable age of onset to non-CHEK2 mutated HM patients, with only 6% of these being clearly identified as therapy-related, and a possible enrichment for recurrent translocation events in P/LP CHEK2 carriers with MDS/AML. Here, CHEK2 is linked to acute myeloid leukemia.